Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • The Department of Neurology
In multifocal motor neuropathy (MMN), high dose of IV immunoglobulin (IVIg) is the only established treatment. Subcutaneous self-infusion with immunoglobulin G (IgG) (SCIG) increases patient autonomy and treatment flexibility, and might be associated with fewer side effects due to lower peak IgG levels. In a recent study of 9 patients with MMN, we reported that SCIG preserves muscle strength for a few months of treatment. Five patients preferred to continue SCIG after the trial and another patient chose to apply SCIG.
Original languageEnglish
JournalNeurology
Volume75
Issue15
Pages (from-to)1377-80
Number of pages4
DOIs
Publication statusPublished - 12 Oct 2010

    Research areas

  • Adult, Cohort Studies, Disability Evaluation, Female, Humans, Immunoglobulins, Infusions, Subcutaneous, Male, Middle Aged, Muscle Strength, Muscle Strength Dynamometer, Neurologic Examination, Polyneuropathies, Self Administration, Statistics, Nonparametric, Time Factors, Treatment Outcome

See relations at Aarhus University Citationformats

ID: 34164470